Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19
C Spinner, R Gottlieb, G Criner, etalJAMA, 2020, online August 2020
Comment
We have seen benefits of remdesivir in patients with severe COVID-19 in terms of time clinical improvement.
We have seen;
Open label RCT remdesivir for 5-days vs 10-days in hospitalised COVID-19 with hypoxia
This page is only available to Crit-IQ subscribers. To view the rest of this review and gain access to our vast array of critical care teaching tools including podcasts, vodcasts, modules,
exam preparation tools, teaching aids and much more, login here, or Become a Member to register
Become a member
Comment
We have seen benefits of remdesivir in patients with severe COVID-19 in terms of time clinical improvement.
We have seen;
This page is only available to Crit-IQ subscribers. To view the rest of this review and gain access to our vast array of critical care teaching tools including podcasts, vodcasts, modules, exam preparation tools, teaching aids and much more, login here, or Become a Member to register